Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 7, 2005, Pages 988-994

  Fang, Jing Yuan ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Inst of Digestive Diseases   (China)

Author keywords

Anticancerous mechanism; Cell cycle; Gastrointestinal cancer; Gene expression; Histone deacetylase inhibitor

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CHLAMYDOCIN; CYCLIC HYDROXAMIC ACID CONTAINING PEPTIDE 1; CYCLIC HYDROXAMIC ACID CONTAINING PEPTIDE 31; DEPSIPEPTIDE; DEPUDECIN; FLUDARABINE; FLUOROURACIL; FR 901228; GAMMA INTERFERON; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INDOMETACIN; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PYROXAMIDE; SCRIPTIDE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; LIVER CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH CANCER; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; DNA, NEOPLASM; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; TRANSCRIPTION, GENETIC;

EID: 21844451163     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03807.x     Document Type: Review

References (69)

1. Plass C. Cancer epigenomics. Hum. Mol. Genet. 2002; 11: 2479-88.
2. Struhl K. Histone acetylation and transcriptional regulatory mechanism. Genes Dev. 1998; 12: 599-606.
3. Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr. Cancer Drug Targets 2003; 3: 219-36.
4. Kim DH, Kim M, Kwon HJ. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J. Biochem. Mol. Biol. 2003; 36: 110-19.
5. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3.p. Science 1996; 272: 408-11.
6. Yang WM, Inouye C, Zeng Y, Bearss D, Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc. Natl Acad. Sci. USA 1996; 93: 12845-50.
7. Emiliani S, Fischle W, Van Lint C, Al-Abed Y, Verdin E. Characterization of a human RPD3 ortholog, HDAC3. Proc. Natl Acad. Sci. USA 1998; 95: 2795-800.
8. Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1.p. Proc. Natl Acad. Sci. USA 1999; 96: 4868-73.
9. Fischle W, Emiliani S, Hendzel MJ et al. A new family of human histone deacetylases related to Saccharomyces cerevisiae HDA1.p. J. Biol. Chem. 1999; 274: 11713-20.
10. Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 2002; 277: 25 748-55.
11. Chen WY, Townes TM. Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc. Natl Acad. Sci. USA 2000; 97: 377-82.
12. Ng HH, Bird A. Histone deacetylases: silencers for hire. Trends Biochem. Sci. 2000; 25: 121-6.
13. waf1/cip1 promoter activation induced by histone deacetylase inhibitor. J. Biol. Chem. 2000; 275: 1371-6.
14. waf1 promoter actvity induced by histone deacetylase inhibitor in HIH3t3 cells. J. Cell. Biochem. 1999; 73: 291-302.
15. Archer SY, Hodin RA. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 1999; 9: 171-4.
16. Siavoshian S, Segain JP, Kornprobst M et al. Butyrate and trichostain A effects on the proliferation/differentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 2000; 46: 507-14.
17. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003; 63: 3637-45.
18. Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 1999; 96: 4592-7.
19. Camphausen K, Burgan W, Cerra M et al. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004; 64: 316-21.
20. Vettese-Dadey M, Grant PA, Hebbes TR, Crane-Robinson C, Allis CD, Workman JL. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J. 1996; 15: 2508-18.
21. WAF1/CIP1 by apicidin, a novel histone deacetylase inhibitor. Biochem. Biophy. Res. Commun. 2001; 281: 866-71.
22. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 2004; 101: 540-5.
23. Komatsu Y, Tomizaki KY, Tsukamoto M et al. Cyclic hydroxamic-acid- containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. Cancer Res. 2001; 61: 4459-66.
24. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001; 48: S20-6.
25. Xiao JJ, Byrd J, Marcucci G, Grever M, Chan KK. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun. Mass Spectrom. 2003; 17: 757-66.
26. Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001; 98: 2865-8.
27. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 2002; 62: 4916-21.
28. Takigawa-Imamura H, Sekine T, Murata M, Takayama K, Nakazawa K, Nakagawa J. Stimulation of glucose uptake in muscle cells by prolonged treatment with scriptide, a histone deacetylase inhibitor. Biosci. Biotechnol. Biochem. 2003; 67: 1499-506.
29. Keen JC, Yan L, Mack KM et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat. 2003; 81: 177-86.
30. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol. Cancer Ther. 2003; 2: 401-8.
31. De Schepper S, Bruwiere H, Verhulst T et al. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J. Pharmacol. Exp. Ther. 2003; 304: 881-8.
32. Garber K. Purchase of Aton spotlights HDAC inhibitors. Nat. Biotechnol. 2004; 22: 364-5.
33. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 2000; 11: 2069-83.
34. Ruefli AA, Ausserlechner MJ, Bernhard D et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilde hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of BID and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 2001; 98: 10833-8.
35. Butler LM, Zhou X, Xu WS et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc. Natl Acad. Sci. USA 2002; 99: 11 700-5.
36. WAF1 regulation. World J. Gastroenterol. 2002; 8: 410-15.
37. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 2002; 13: 1-13.
38. Shin HJ, Back KH, Jeon AH et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003; 22: 3853-8.
39. Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett. 2003; 554: 347-50.
40. Siddiqui H, Solomon DA, Gunawardena RW, Wang Y, Knudsen ES. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol. Cell Biol. 2003; 23: 7719-31.
41. Han JW, Ahn SH, Park SH et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 2000; 60: 6068-74.
42. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and hisone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 1999; 21: 103-7.
43. Maggio SC, Rosato RR, Kramer LB et al. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004; 64: 2590-600.
44. Terui T, Murakami K, Takimoto R et al. Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res. 2003; 63: 8948-54.
45. Sasakawa Y, Naoe Y, Noto T et al. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem. Pharmacol. 2003; 66: 897-906.
46. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 2002; 97: 290-6.
47. Mie Lee Y, Kim SH, Kim HS et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 2003; 300: 241-6.
48. Kim MS, Kwon HJ, Lee YM et al. Deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 2001; 7: 437-43.
49. Fang JY, Chen YX, Lu J et al. Epigenetic modification regulates expression of tumor-associated genes and cell cycle in human colon cancer cell lines Colo-320 and SW1116. Cell Res. 2004; 13: 217-26.
50. WAF1 expression in human colon cancer cell lines. World J. Gastroenterol. 2004; 10: 2643-6.
51. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J. Nutr. 2002; 132: 1012-17.
52. Chen Z, Clark S, Birkeland M et al. Induction and super-induction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 2002; 188: 127-40.
53. Chen ZY, Rex S, Tseng CC. Kruppel-like factor 4 is transactivated by butyrate in colon cancer cells. J. Nutr. 2004; 134: 792-8.
54. Kraker AJ, Mizzen CA, Hartl BG, Miin J, Allis CD, Merriman RL. Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. Mol. Cancer Ther. 2003; 2: 401-8.
55. Kobayashi H, Tan EM, Fleming SE. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Int. J. Cancer 2004; 109: 207-13.
56. Donadelli M, Costanzo C, Faggioli L et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol. Carcinog. 2003; 38: 59-69.
57. Sato N, Ohta T, Kitagawa H et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int. J. Oncol. 2004; 24: 679-85.
58. Zhao S, Venkatasubbarao K, Li S, Freeman JW. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. Cancer Res. 2003; 63: 2624-30.
59. Yamashita Y, Shimada M, Harimoto N et al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 2003; 103: 572-6.
60. Choi HS, Lee JH, Park JG, Lee YI. Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. Biochem. Biophys. Res. Commun. 2002; 296: 1005-12.
61. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52: 6735-40.
62. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY. Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J. Gastroenterol. Hepatol. 2004; 19: 218-24.
63. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001; 12: 294-300.
64. Terao Y, Nishida J, Horiuchi S et al. Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int. J. Cancer 2001; 92: 257-67.
65. D'argenio G, Cosenza V, Cave MD et al. Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. Gastroenterology 1996; 110: 1727-34.
66. McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibers and protection against large bowel cancer in a rat model. Gut 1993; 34: 386-91.
67. McIntyre A, Young GP, Taranto T, Gibson PR, Ward PB. Different fibers have different regional effects on luminal contents of rat colon. Gastroenterology 1991; 101: 1274-81.
68. Scheppach W, Bartram P, Richter A et al. The effect of short-chain fatty acids on the human colonic mucosa in vitro. J. Parenter. Enter. Nutr. 1992; 16: 43-8.
69. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002; 1: 287-99.